All In Biotech

Drug Trial Radar · NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 16, 2024

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
KaliVir ImmunotherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

Conditions

  • Solid Tumor, Adult
  • Microsatellite Stable Colorectal Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Cervical Cancer
  • Kidney Cancer
  • Renal Cell Carcinoma
  • Melanoma Stage IV
  • Merkel Cell Carcinoma of Skin
  • Mesothelioma
  • Non-small Cell Lung Cancer
  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Urothelial Carcinoma Bladder
  • Squamous Cell Carcinoma

Interventions

  • VET3-TGIDrug

    Oncolytic vaccinia virus engineered with immunomodulatory transgenes

  • AtezolizumabDrug

    anti-pd-L1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events with VET3-TGI alone or in combination with atezolizumabTime frame: 108 months
  2. Incidence of dose limiting toxicities reported with VET3-TGI alone or in combination with atezolizumabTime frame: 4 weeks
  3. Determine the recommended Phase 2 doseTime frame: 4 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UC Irvine Health

    Orange, California · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Community Health Network

    Indianapolis, Indiana · Active not recruiting

  • UPMC- Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Mary Crowley Cancer Research/Sarah Cannon Research Institute

    Dallas, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Washington, Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.